STERIS (NYSE:STE – Get Free Report) posted its quarterly earnings data on Tuesday. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.16, RTT News reports. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.89%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the company posted $2.00 EPS. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.
STERIS Trading Down 1.5 %
Shares of NYSE:STE traded down $3.70 during midday trading on Friday, hitting $235.98. 421,762 shares of the stock traded hands, compared to its average volume of 488,756. The stock has a market capitalization of $23.33 billion, a PE ratio of 61.76 and a beta of 0.83. The business’s 50 day moving average is $225.17 and its two-hundred day moving average is $222.88. The company has a quick ratio of 2.36, a current ratio of 3.08 and a debt-to-equity ratio of 0.49. STERIS has a one year low of $195.47 and a one year high of $243.37.
STERIS Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 20th. Stockholders of record on Thursday, September 5th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 0.97%. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, September 5th. STERIS’s dividend payout ratio is 54.45%.
Insider Activity
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on STE. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research report on Thursday. Piper Sandler reissued a “neutral” rating and issued a $225.00 price target (up from $220.00) on shares of STERIS in a research note on Friday, May 10th. JMP Securities reissued a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research note on Wednesday. StockNews.com downgraded shares of STERIS from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $243.60.
Check Out Our Latest Research Report on STE
About STERIS
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Recommended Stories
- Five stocks we like better than STERIS
- What Does a Stock Split Mean?
- The Cannabis Sector: Profitability Takes Center Stage
- What Makes a Stock a Good Dividend Stock?
- Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
- Top Stocks Investing in 5G Technology
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.